54.09% -0.0119

Syros Pharmaceuticals Inc (SYRS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario

Syros Pharmaceuticals Inc Borsa (SYRS) Ultime notizie

Syros Pharmaceuticals Inc (SYRS)

Syros Pharmaceuticals Inc Borsa (SYRS) Ultime notizie

Bronstein, Gewirtz and Grossman, LLC Encourages Syros Pharmaceuticals, Inc. (SYRS) Stockholders to Inquire about Securities Investigation - ACCESS Newswire

Levi & Korsinsky Reminds Syros Pharmaceuticals Investors of the Ongoing Investigation into Potential Violations of Securities LawsSYRS - ACCESS Newswire

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Receives Consensus Rating of “Hold” from Analysts - Defense World

SYROS PHARMACEUTICALS Earnings Preview: Recent $SYRS Insider Trading, Hedge Fund Activity, and More - Nasdaq

Syros Pharmaceuticals (NASDAQ:SYRS) Now Covered by StockNews.com - Defense World

Blood Cancer Treatment Market Sees Accelerated Growth Across the 7MM Amid Rising Incidence and Breakthroughs | DelveInsight - GlobeNewswire Inc.

Syros Pharmaceuticals (NASDAQ:SYRS) Coverage Initiated by Analysts at StockNews.com - Defense World

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Receives Consensus Recommendation of “Hold” from Analysts - Defense World

StockNews.com Begins Coverage on Syros Pharmaceuticals (NASDAQ:SYRS) - Defense World

Press Release Distribution & PR Platform - ACCESS Newswire

Shareholders that lost money on Syros Pharmaceuticals, Inc.(SYRS) should contact Levi & Korsinsky about Securities Fraud InvestigationSYRS - ACCESS Newswire

SYRS ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Syros Pharmaceuticals, Inc. Shareholders Who Lost Money - ACCESS Newswire

StockNews.com Initiates Coverage on Syros Pharmaceuticals (NASDAQ:SYRS) - Defense World

Rege Nephro buys Tamibarotene-related assets from Syros Pharmaceuticals - MSN

Rege Nephro Acquires Assets from Syros Pharmaceuticals (SYRS) - GuruFocus

Rege Nephro Acquires Key Assets from Syros Pharmaceuticals (SYRS - GuruFocus

Rege Nephro Acquires Key Assets from Syros Pharmaceuticals (SYRS) | SYRS Stock News - GuruFocus

Rege Nephro Acquires Tamibarotene-Related Assets from Syros Pharmaceuticals for U.S. Clinical Trials | SYRS Stock News - GuruFocus

Rege Nephro Acquires Tamibarotene-Related Assets from Syros Phar - GuruFocus

Rege Nephro Acquires Tamibarotene-Related Assets from Syros Pharmaceuticals for U.S. Clinical Trials - digitalmore.co

Major Kidney Disease Drug Acquisition: Rege Nephro Takes Over Syros' Phase 2 Asset - Stock Titan

Syros Pharma pulls out of deal with RaQualia - The Pharma Letter

Syros Pharmaceuticals (NASDAQ:SYRS) Coverage Initiated at StockNews.com - Defense World

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Given Average Recommendation of “Hold” by Brokerages - Defense World

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Short Interest Up 345.9% in March - Defense World

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Receives $3.33 Average PT from Brokerages - Defense World

Syros Pharmaceuticals (SYRS) to Release Earnings on Wednesday - Defense World

Dow Dips Over 200 Points; US Industrial Production Increases More than Expected - Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga India

Analyze Syros Pharmaceuticals Inc (NASDAQ: SYRS) Before Investing. - stocksregister.com

12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga

Finance Watch: Sutro Halves Workforce, Cuts Lead ADC And CEO Moves On - Citeline News & Insights

12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga

Pre-market Movers: HCTI, HEPA, ZYXI, SYRS ... - RTTNews

US Stocks Mixed; Kohl's Shares Plunge After Q4 Results - Benzinga

Aptevo Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:APVO - Benzinga

Syros Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire

Syros Pharmaceuticals settles debt with Oxford Finance By Investing.com - Investing.com South Africa

Syros Pharmaceuticals settles debt with Oxford Finance - Investing.com India

Why US Stock Futures Are Rising TodayInvesco QQQ Trust, Series 1 (NASDAQ:QQQ), SPDR S&P 500 (ARCA:SPY) - Benzinga

Syros Pharmaceuticals, Inc. Announces Cessation of Gerald Quirk as Chief Executive Officer, Effective March 01, 2025 - Marketscreener.com

Syros Pharmaceuticals, Inc. Announces Management Changes -February 28, 2025 at 04:15 pm EST - Marketscreener.com

Stocks to Watch: Toro, Syros Pharmaceuticals - MarketWatch

Simile a SYRS